AI assistant
Sending…
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2012
Nov 19, 2012
30583_dirs_2012-11-19_4f6d19c6-5279-4194-af5e-af7a76f648f0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2012-11-16
Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-11-16 | Common Stock | M | 8000 | $12.99 | Acquired | 175691 | Direct |
| 2012-11-16 | Common Stock | S | 8000 | $48.0457 | Disposed | 167691 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-11-16 | Stock Option (right to buy) Common Stock | $12.99 | M | 8000 | Disposed | 2016-05-10 | Common Stock (8000) | Direct |
Footnotes
F1: The price in Column 4 is a weighted average price. The prices actually received ranged from $47.78 to $48.39. The reporting person will provide to the issue, any security holder of the issuer, or SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: Original option grant vests 6/48th on November 11, 2006 and 1/48th on the 11th day of every month thereafter.
More from BIOMARIN PHARMACEUTICAL INC
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 4
Interim / Quarterly Report
2026
May 5
Report Publication Announcement
2026
May 4
M&A Activity
2026
Apr 27
M&A Activity
2026
Apr 23
Annual Report
2026
Apr 21
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19